• SYGNIS further executing on strategy by expanding its product portfolio
• SunScript™ Reverse Transcriptase, one of the most thermostable and fastest enzymes commercially available today
• Products available through international distribution partners in North America, Asia and Europe and SYGNIS online shop
Madrid, Spain and Heidelberg, Germany, April 20th, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the global launch of SunScript™ Reverse Transcriptase, the Company’s second product line for a multitude of applications in molecular biology and diagnostics research.
SYGNIS’ SunScript™ product line covers a series of kits based on novel proprietary engineered reverse transcriptase (RT) derived from the well characterized human immunodeficiency virus (HIV-1) and which today is one of the most thermostable and fastest enzyme commercially available. RTs are commonly used in molecular biology to convert genetic information from RNA molecules back to DNA, enabling a number of downstream analyses of RNA molecules using DNA analysis methods such as next generation sequencing or polymerase chain reaction (PCR) in gene expression profiling and molecular diagnostics.
SunScript™ enzymes provide an extreme thermostability allowing RT reactions to take place at elevated temperatures up to 85°C resolving even the most complicated RNA structures to obtain a faithful picture of the original genetic information. Additional advantages consist in the high reaction speed of the enzymes, an exquisite sensitivity, and the ability to readily transcribe even the longest RNAs from the mammalian genome. The first products launched are SunScript™ RT RNaseH+ and SunScript™ RT RNaseH- enzymes optimized for use in PCR analysis and for the construction of complementary DNA (cDNA) libraries needed for example in next generation sequencing applications.
SYGNIS has developed a broad range of proprietary technologies addressing key challenges in molecular biology such as limited amounts of DNA and RNA in a sample and the necessity to translate RNA into DNA to make it applicable for current sequencing technologies and platforms. The superior features of SYGNIS’ TruePrime™ whole genome amplification products together with the outstanding performance of the SunScript™ RT product line make SYGNIS products highly attractive for a broad range of industrial next generation sequencing applications and downstream analyses and position the Company as a leading provider of innovative and superior tools for DNA amplification and sequencing in fast growing markets such as human genetics, oncology, molecular diagnostics and personalized medicine. “We are very proud and excited about the launch of SunScript™, our second product line of kits providing different forms of novel, highly thermostable reverse transcriptase. This launch is another milestone and is further building our corporate product and commercialization strategy. SunScript™ proves that SYGNIS development strategy is well on track,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “The new product family perfectly fits in our already existing portfolio of innovative products. In addition, it provides us with the opportunity to bundle technologies and products to increase the value of our tools for researchers in the fast growing field of molecular biology and next generation sequencing. We are fully committed to sustaining this strong momentum and we will continue to further grow our portfolio by adding highly innovative products.”
The SunScript™ RT products are in stock and will be globally commercialized mainly through the Company’s various international distributors as well as the SYGNIS online shop under www.sygnis.com/shop.
SYGNIS has started an extensive promotional mailing campaign to all potential users in the molecular biology field. The Company plans a wide range of additional marketing events around the product launch including presentations at key international scientific meetings and conferences including the AACR (American Association for Cancer Research) Annual Meeting 2015 in the US and the meeting of the European Society of Human Genetics (ESHG) in the UK to name just two. SYGNIS is currently developing a series of further high temperature single-step RT-PCR kits. In addition, the Company plans to combine the products from its SunScript™ product line with its proprietary TruePrime™ technologies for primer-free whole genome amplification to enable high-quality complete transcriptome (total RNA in a cell) analyses from low input material and single cells.
About SunScript™ RT
SunScript™ Reverse Transcriptase is a reverse transcriptase that has been engineered for high thermostability, based on the well characterized human immunodeficiency virus RT (HIV-1 RT). The enzyme is active up to temperatures of 85°C. SunScript™ Reverse Transcriptase will be available in two versions. In its RNaseH+ version, the enzyme shows RNA-dependent polymerase activity as well as RNaseH (ribonuclease that cleaves the RNA in a DNA/RNA duplex) activity. This product is optimized for synthesis of complementary DNA (cDNA) as well as for use in reverse transcriptase (RT) PCR and quantitative PCR reactions.
SunScript™ RT RNaseH- has been determined to be free of RNaseH activity which permit high yields of full length cDNA synthesis on long RNA molecules for the construction of cDNA libraries needed for example in next generation sequencing applications. In addition, the elimination of RNaseH activity provides SunScript™ RT RNaseH- with a lower error rate and an improved processivity at higher temperatures that allows resolution of RNA folds and less nonspecific binding by the DNA primer.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi®, licensed to an industry leading partner and is currently developing two own product lines, TruePrime™ based on its proprietary TruePrime™ technology for whole genome amplification and SunScript™ Reverse Transcriptase to convert genetic information from RNA molecules back to DNA. Both product lines are addressing key challenges in the fast growing fields of molecular biology and next neneration sequencing applications. The first TruePrime™ products for single cell as well as whole genome DNA amplification were launched beginning 2015.
Help employers find you! Check out all the jobs and post your resume.
• SunScript™ Reverse Transcriptase, one of the most thermostable and fastest enzymes commercially available today
• Products available through international distribution partners in North America, Asia and Europe and SYGNIS online shop
Madrid, Spain and Heidelberg, Germany, April 20th, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the global launch of SunScript™ Reverse Transcriptase, the Company’s second product line for a multitude of applications in molecular biology and diagnostics research.
SYGNIS’ SunScript™ product line covers a series of kits based on novel proprietary engineered reverse transcriptase (RT) derived from the well characterized human immunodeficiency virus (HIV-1) and which today is one of the most thermostable and fastest enzyme commercially available. RTs are commonly used in molecular biology to convert genetic information from RNA molecules back to DNA, enabling a number of downstream analyses of RNA molecules using DNA analysis methods such as next generation sequencing or polymerase chain reaction (PCR) in gene expression profiling and molecular diagnostics.
SunScript™ enzymes provide an extreme thermostability allowing RT reactions to take place at elevated temperatures up to 85°C resolving even the most complicated RNA structures to obtain a faithful picture of the original genetic information. Additional advantages consist in the high reaction speed of the enzymes, an exquisite sensitivity, and the ability to readily transcribe even the longest RNAs from the mammalian genome. The first products launched are SunScript™ RT RNaseH+ and SunScript™ RT RNaseH- enzymes optimized for use in PCR analysis and for the construction of complementary DNA (cDNA) libraries needed for example in next generation sequencing applications.
SYGNIS has developed a broad range of proprietary technologies addressing key challenges in molecular biology such as limited amounts of DNA and RNA in a sample and the necessity to translate RNA into DNA to make it applicable for current sequencing technologies and platforms. The superior features of SYGNIS’ TruePrime™ whole genome amplification products together with the outstanding performance of the SunScript™ RT product line make SYGNIS products highly attractive for a broad range of industrial next generation sequencing applications and downstream analyses and position the Company as a leading provider of innovative and superior tools for DNA amplification and sequencing in fast growing markets such as human genetics, oncology, molecular diagnostics and personalized medicine. “We are very proud and excited about the launch of SunScript™, our second product line of kits providing different forms of novel, highly thermostable reverse transcriptase. This launch is another milestone and is further building our corporate product and commercialization strategy. SunScript™ proves that SYGNIS development strategy is well on track,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “The new product family perfectly fits in our already existing portfolio of innovative products. In addition, it provides us with the opportunity to bundle technologies and products to increase the value of our tools for researchers in the fast growing field of molecular biology and next generation sequencing. We are fully committed to sustaining this strong momentum and we will continue to further grow our portfolio by adding highly innovative products.”
The SunScript™ RT products are in stock and will be globally commercialized mainly through the Company’s various international distributors as well as the SYGNIS online shop under www.sygnis.com/shop.
SYGNIS has started an extensive promotional mailing campaign to all potential users in the molecular biology field. The Company plans a wide range of additional marketing events around the product launch including presentations at key international scientific meetings and conferences including the AACR (American Association for Cancer Research) Annual Meeting 2015 in the US and the meeting of the European Society of Human Genetics (ESHG) in the UK to name just two. SYGNIS is currently developing a series of further high temperature single-step RT-PCR kits. In addition, the Company plans to combine the products from its SunScript™ product line with its proprietary TruePrime™ technologies for primer-free whole genome amplification to enable high-quality complete transcriptome (total RNA in a cell) analyses from low input material and single cells.
About SunScript™ RT
SunScript™ Reverse Transcriptase is a reverse transcriptase that has been engineered for high thermostability, based on the well characterized human immunodeficiency virus RT (HIV-1 RT). The enzyme is active up to temperatures of 85°C. SunScript™ Reverse Transcriptase will be available in two versions. In its RNaseH+ version, the enzyme shows RNA-dependent polymerase activity as well as RNaseH (ribonuclease that cleaves the RNA in a DNA/RNA duplex) activity. This product is optimized for synthesis of complementary DNA (cDNA) as well as for use in reverse transcriptase (RT) PCR and quantitative PCR reactions.
SunScript™ RT RNaseH- has been determined to be free of RNaseH activity which permit high yields of full length cDNA synthesis on long RNA molecules for the construction of cDNA libraries needed for example in next generation sequencing applications. In addition, the elimination of RNaseH activity provides SunScript™ RT RNaseH- with a lower error rate and an improved processivity at higher temperatures that allows resolution of RNA folds and less nonspecific binding by the DNA primer.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi®, licensed to an industry leading partner and is currently developing two own product lines, TruePrime™ based on its proprietary TruePrime™ technology for whole genome amplification and SunScript™ Reverse Transcriptase to convert genetic information from RNA molecules back to DNA. Both product lines are addressing key challenges in the fast growing fields of molecular biology and next neneration sequencing applications. The first TruePrime™ products for single cell as well as whole genome DNA amplification were launched beginning 2015.
Help employers find you! Check out all the jobs and post your resume.
